Company Analysis
Sign in

Cellectis S.A. (CLLS)

Nasdaq: CLLS · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2014
Full chart Alerts Compare
Grade5.6
◀ Past 4.9● Present 5.4▶ Future 6.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Cellectis S.A.

Nine metrics read from its own filings, by tense
Headline grade
5.6/10
◀ Past4.930% of the headline
● Present5.440% of the headline
▶ Future6.730% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.9/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.0/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 80th percentile among 159 sector filers · read for itself

From the record

Cellectis S.A.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.1/10

What has it actually done, year after year?

+5.6% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 31st percentile among 102 sector filers · read for its customers

From the record

Cellectis S.A.'s 10 filed years say what it did: revenue went from $45 million in fiscal 2016 to $73 million in fiscal 2025, up 5.6% a year; it rose in 4 of 9 years; the deepest fall was 99% from fiscal 2020 to fiscal 2023; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span5.6%bottom 37% of its family
  • the share of years revenue rosebottom 31% of its family
  • the share of filed years with a profitbottom 31% of its family
  • the deepest fall from a revenue peak98.5%bottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
3.9/10

How has it treated the people who own it?

SI estimate 3.9/10, confidence 35 of 100 (one part).

weight 22% of this tense · 39th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 39% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cellectis S.A.'s shareholder treatment is put at 3.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 39% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
4.4/10

Is it financially healthy right now?

ROE -89%: lost 89¢ per shareholder dollar. Leverage 77%: owes 77¢ per asset dollar.

weight 45% of this tense · 44th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Cellectis S.A. lost about 89 cents for every dollar of shareholders' money, and gross profitability: its products earned about 22 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 77 cents per dollar of assets, and net share issuance: its share count grew 10.7% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 25% of its family
  • return on equitybottom 32% of its family
  • gross profit against assetstop 44% of its family
  • the share count against the year beforetop 37% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
7.0/10

How strong is its position in its industry?

top 30% of 102 in its family; net margin -92.7%.

weight 33% of this tense · 70th percentile among 102 sector filers · read for its customers

From the record

Cellectis S.A.'s standing among 102 graded names in its industry family: revenue of $73 million in fiscal 2025 ranks in the top 35% by size; a net margin of -92.7% ranks in the top 35%; revenue growth of 56.1% a year over the last 3 filed years ranks in the top 18% (its annual reports).

What it rests on

  • revenue against the family$72.9Mtop 35% of its family
  • net margin-92.7%top 35% of its family
  • three-year revenue growth56.1%top 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 130 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 130 members with one.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned
family median, 130 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cellectis S.A.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 130 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.7/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
6.1/10

How much room does it have to grow?

top 39% of 92 in its family for room to expand.

weight 45% of this tense · 61st percentile among 92 sector filers · read for itself

From the record

Cellectis S.A.'s room to grow, from the newest filed statements (fiscal 2025): cash of $62 million against no long-term debt tagged leaves 18.9% of its assets as net cash, bottom 36% of its family; cash from operations less capital spending is -57.2% of revenue (top 32%); a gross margin of 100% (top 4%); research spending of 128.2% of revenue (bottom 43%) (its annual report).

What it rests on

  • cash less debt against assets18.9%bottom 36% of its family
  • cash from operations less capital spending against revenue-57.2%top 32% of its family
  • gross margin100.0%top 4% of its family
  • research spending against revenue128.2%bottom 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
7.2/10

What could actually drive growth from here?

top 28% of 100 in its family for growth drivers.

weight 33% of this tense · 72nd percentile among 100 sector filers · read for its customers

From the record

Cellectis S.A.'s growth drivers, from the filed years to fiscal 2025: revenue grew 56.1% a year over the last three filed years against 5.6% over all 10, speeding up (top 6% of its family); the newest year grew 75.8% (top 24%); research spending grew -1.4% a year (bottom 44%); capital spending grew -1% a year (top 27%) (its annual reports). Cellectis S.A. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+50.5 points a yeartop 6% of its family
  • the newest year's revenue growth75.8%top 24% of its family
  • three-year growth of research spending-1.4%bottom 44% of its family
  • three-year growth of capital spending-1.0%top 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
7.1/10

Did its newest year beat what its own record pointed to?

top 29% of 72 in its family for expectations against reality.

weight 22% of this tense · 71st percentile among 72 sector filers · read for its shareholders

From the record

Cellectis S.A.'s newest year against its own record: revenue of $73 million in fiscal 2025 came in 19.5% above the $61 million its prior three years' pace pointed to (top 39% of its family); net income of $68 million against a prior three-year average of $86 million (top 42%); a net margin of -92.7% against losses larger than its revenue before (top 8%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace19.5%top 39% of its family
  • net income against the prior three years' average+22%top 42% of its family
  • net margin against its prior averageup more than 100 pointstop 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton CLLS · research, not advice